克雷珠单抗在PSEN1 Glu280Ala突变携带者中的2期试验
这项2期随机双盲安慰剂对照试验在哥伦比亚纳入252名认知未受损的PSEN1 Glu280Ala突变携带者及非携带者,评估克雷珠单抗对临床终点的影响。结果显示,治疗5-8年未显著延缓API ADAD复合评分或FCSRT-CI的年变化率,也未显著影响淀粉样斑块清除或其它生物标志物。
要点
- 克雷珠单抗治疗5-8年未显著改善主要临床终点。
- 次要和探索性终点亦未显示显著疗效。
- robust纤维状淀粉样斑块清除可能是临床疗效的必要条件。
核心结论
- 克雷珠单抗治疗5-8年未显著改善认知未受损的PSEN1 Glu280Ala突变携带者的主要临床结局。
研究设计与样本
- 2期随机双盲安慰剂对照单中心试验,纳入252名30-60岁认知未受损的PSEN1 Glu280Ala突变携带者及非携带者。
- 携带者按1:1随机接受克雷珠单抗或安慰剂,非携带者接受安慰剂,比例1:2。
主要发现
- 严重不良事件发生率:克雷珠单抗组27%(23/84),安慰剂组25%(21/84),无死亡。
临床怎么用
- 克雷珠单抗未显示临床获益,不推荐用于认知未受损的PSEN1 Glu280Ala突变携带者。
- 未来抗淀粉样β治疗试验可能需要确保 robust 的纤维状淀粉样斑块清除。
局限性
- 单中心研究,结果外推需谨慎。
- 主要终点基于随机且至少接受一剂的研究药物者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To have maximal benefit, Alzheimer's disease-modifying treatments might need to be started before the onset of clinical symptoms. Mutations of the PSEN1 gene are inherited as fully penetrant, autosomal-dominant traits, which almost always result in the clinical onset of Alzheimer's disease before the age of 65 years. We aimed to evaluate the efficacy, including possible delayed emergence of cognitive impairment, and safety of crenezumab, an anti-amyloid monoclonal antibody, in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at high imminent risk of developing symptoms due to Alzheimer's disease. METHODS: This 5-8-year common-close, double-blind, placebo-controlled, single-centre trial screened kindred members aged 30-60 years from the main health-care site in Medellín, Colombia. Participants who were cognitively unimpaired and carried the PSEN1Glu280Ala autosomal-dominant mutation were randomly assigned 1:1 to receive placebo or subcutaneous crenezumab (investigators and participants were masked to treatment allocation), with an initial 300 mg dose every 2 weeks that increased to 720 mg every 2 weeks, and a later optional increase to 60 mg/kg intravenously every 4 weeks. Randomisation was stratified by age, education, APOE ɛ4 carrier status, and baseline Clinical Dementia Rating. Mutation non-carriers received placebo and were included in a 1:2 ratio of non-carriers to carriers to maintain genotype masking and include a genetic kindred control. Dual primary outcomes were the annualised rates of change in the Alzheimer's Prevention Initiative (API) preclinical autosomal-dominant Alzheimer's disease (ADAD) composite test total score and Free and Cued Selective Reminding Test-Cueing Index (FCSRT-CI) assessed in randomised participants who received at least one dose of the study drug, according to treatment assignment. Primary endpoints were assessed with a random coefficient regression model with a missing-at-random assumption adjusting for randomisation factors. Safety endpoints for mutation carriers were assessed in randomised participants who received at least one dose of the study drug. This trial is registered with ClinicalTrials.gov (NCT01998841) and is completed. FINDINGS: 619 Colombian API registrants were prescreened, 315 were assessed for eligibility, and 252 were enrolled (crenezumab-carrier, n=85; placebo-carrier, n=84; placebo-non-carrier, n=83; 160 [63%] women and 92 [37%] men) between Dec 20, 2013, and Feb 27, 2017. 237 (94%) completed the trial, with final data collection on March 22, 2022. The annualised rate of change in the API ADAD composite was -1·10 (SE 0·29) in the crenezumab group and -1·43 (0·29) in the placebo group (between-group difference 0·33 [95% CI -0·48 to 1·13]; p=0·43). The annualised rate of change in FCSRT-CI was -0·03 (0·00) in the crenezumab group and -0·04 (0·00) in the placebo group (between-group difference 0·01 [0·00 to 0·02]; p=0·16). All participants had at least one adverse event; serious adverse events occurred in 23 (27%) of 84 in the crenezumab group and 21 (25%) of 84 in the placebo group. No fatalities occurred. INTERPRETATION: Crenezumab therapy administered for 5-8 years did not result in significant benefits on our primary clinical outcomes in cognitively unimpaired participants predisposed to developing ADAD dementia; secondary and exploratory outcomes also showed no significant effect on removal of amyloid plaques or other clinical or biomarker outcomes. Together with the results of other anti-amyloid β trials, robust fibrillar amyloid removal appears necessary for clinical efficacy in people with elevated brain amyloid. This study will further inform the biomarker, cognitive, and clinical trajectory of preclinical ADAD, the risk of clinical progression in amyloid-positive and amyloid-negative mutation carriers, and the size and design of future secondary and primary prevention trials. FUNDING: US National Institute on Aging (NIA), Banner Alzheimer's Institute, Genentech, F Hoffmann-La Roche.
引用
- Tariot PN, Lopera FS, Ríos-Romenets S, et al. Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2026. PMID: 41579901. doi:10.1016/S1474-4422(25)00426-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。